Beteiligte Stoffe
| Rolle | Name | HCID | Einwaage |
|---|
| Edukt | Prostaglandin E2 | HCID 5280360 | — |
| Edukt | 16,16-Dimethyl-pge2 | HCID 5283066 | — |
| Produkt | 16,16-Dimethylprostaglandin E | HCID 5283058 | — |
Reaktionsschritte
Further, following the procedure of Preparation 16, but using in place of the C-15 unsubstituted PGE2 -type compound of Preparation 16 and above, the 15-methyl and 15-methyl ether PGE2 -type compounds described above, there are obtained the corresponding 15-methyl and 15-methyl ether PGE1 -type compounds of either 15-epimeric configuration in both free acid and methyl ester form. Further, following the procedure of Preparation 16 but using in place of the C-16 unsubstituted PGE2 -type compound therein the 16-methyl or 16,16-dimethyl-PGE2 -type compounds described above there are obtained the corresponding 16-methyl or 16,16-dimethyl-PGE1 -type compounds of this invention. Finally, following the procedure of Preparation 16, but using the various 17-substituted phenyl PGE2 -type compounds described above there are obtained the corresponding 17-substituted phenyl-PGE1 -type compounds. The compounds in this paragraph represent the nvel PGE1 -type compounds of this invention.
Herkunft & Nachweise
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patentnummer | US04029693 |
|---|
| Quelldatensatz | uspto-grants-1977_06 |
|---|
| ORD ID | ord-9bb4331f5b84424f91f7cbe19b802e63 |
|---|
| Quellennotiz | uspto-grants-1977_06 |
|---|